相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Stephan R. Bohl et al.
BLOOD ADVANCES (2021)
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
Can Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Santiago Barrio et al.
HAEMATOLOGICA (2020)
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs
Marco De Dominici et al.
BLOOD (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Quantitative Proteomics of the Cancer Cell Line Encyclopedia
David P. Nusinow et al.
CELL (2020)
Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome
Ahmed Mohamed et al.
PLOS ONE (2020)
Rapid and deep-scale ubiquitylation profiling for biology and translational research
Namrata D. Udeshi et al.
NATURE COMMUNICATIONS (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Non-genetic mechanisms of therapeutic resistance in cancer
Jean-Christophe Marine et al.
NATURE REVIEWS CANCER (2020)
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Christian Steinebach et al.
CHEMICAL SCIENCE (2020)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
Jiye Liu et al.
LEUKEMIA (2019)
Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia
Lukas Janker et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Suhas Vasaikar et al.
CELL (2019)
The PRIDE database and related tools and resources in 2019: improving support for quantification data
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2019)
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
Maria Luz Morales et al.
SCIENTIFIC REPORTS (2019)
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Matthias Brand et al.
CELL CHEMICAL BIOLOGY (2019)
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Florian Bellutti et al.
CANCER DISCOVERY (2018)
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity
Quinlan L. Sievers et al.
BLOOD (2018)
Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13
Claudio Alfieri et al.
NATURE (2018)
UBE2G1 governs the destruction of cereblon neomorphic substrates
Gang Lu et al.
ELIFE (2018)
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
Natalia Martinez-Soria et al.
CANCER CELL (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
Nianhang Chen et al.
CLINICAL PHARMACOKINETICS (2017)
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
S. S. Chavan et al.
BLOOD CANCER JOURNAL (2017)
TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
Yi Tao et al.
ONCOTARGET (2017)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Morihiko Sagawa et al.
CLINICAL CANCER RESEARCH (2017)
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Esther A. Zaal et al.
CANCER & METABOLISM (2017)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang et al.
CELL (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity
Ruth Eichner et al.
NATURE MEDICINE (2016)
Proteomic maps of breast cancer subtypes
Stefka Tyanova et al.
NATURE COMMUNICATIONS (2016)
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
Dominik Dytfeld et al.
ONCOTARGET (2016)
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Ruben Niesvizky et al.
LEUKEMIA & LYMPHOMA (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
Peter V. Hornbeck et al.
NUCLEIC ACIDS RESEARCH (2015)
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Theresa Placke et al.
BLOOD (2014)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
C. J. Heuck et al.
LEUKEMIA (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing
Dirk Heck et al.
NATURE BIOTECHNOLOGY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Integrated proteomic analysis of post-translational modifications by serial enrichment
Philipp Mertins et al.
NATURE METHODS (2013)
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4
Xiangao Huang et al.
BLOOD (2012)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
CDK6 kinase activity is required for thymocyte development
Miaofen G. Hu et al.
BLOOD (2011)
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
Lars Anders et al.
CANCER CELL (2011)
Global quantification of mammalian gene expression control
Bjoern Schwanhaeusser et al.
NATURE (2011)
E2F transcription factor-1 regulates oxidative metabolism
Emilie Blanchet et al.
NATURE CELL BIOLOGY (2011)
Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase
Hiroyuki Niida et al.
GENES & DEVELOPMENT (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
Bijay Nair et al.
BLOOD (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Paola E. Leone et al.
CLINICAL CANCER RESEARCH (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Linda B. Baughn et al.
CANCER RESEARCH (2006)
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma
S Ely et al.
CANCER RESEARCH (2005)
分享论文
